{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:37:46Z","timestamp":1793831866177,"version":"4.6.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-024-00782-5","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T10:40:26Z","timestamp":1717065626000},"page":"1082-1101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Targeting a lineage-specific PI3K\u0263\u2013Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule"],"prefix":"10.1038","volume":"5","author":[{"given":"Lois M.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-0887","authenticated-orcid":false,"given":"Justine C.","family":"Rutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Duchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Arang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Pasquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duong","family":"Ho Nhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8471-6641","authenticated-orcid":false,"given":"Shane T.","family":"Killarney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4194-7204","authenticated-orcid":false,"given":"Hazel X.","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Namor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Culeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-3662","authenticated-orcid":false,"given":"B\u00e9rang\u00e8re","family":"Lombard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-8842","authenticated-orcid":false,"given":"Damarys","family":"Loew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6119-6084","authenticated-orcid":false,"given":"Danielle L.","family":"Swaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4902-337X","authenticated-orcid":false,"given":"Nevan J.","family":"Krogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Brunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lodie","family":"Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Verdi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Amblard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiane","family":"Fodil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4376-4097","authenticated-orcid":false,"given":"Marie","family":"Sebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-8766","authenticated-orcid":false,"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Fenouille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-6262","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Itzykson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-4921","authenticated-orcid":false,"given":"Camille","family":"Lobry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Benajiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Forget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6979","authenticated-orcid":false,"given":"Anthony R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5887-2253","authenticated-orcid":false,"given":"Kris C.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3997-9282","authenticated-orcid":false,"given":"Alexandre","family":"Puissant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"782_CR1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony, S., Stahl, M. & Stone, R. M. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 98, 502\u2013526 (2023).","journal-title":"Am. J. Hematol."},{"key":"782_CR2","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum, F. R. et al. Age and acute myeloid leukemia. Blood 107, 3481\u20133485 (2006).","journal-title":"Blood"},{"key":"782_CR3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali, R. S., Pratz, K. W. & Lai, C. Recent advances in targeted therapies in acute myeloid leukemia. J. Hematol. Oncol. 16, 29 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"782_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo, C. D. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133, 7\u201317 (2019).","journal-title":"Blood"},{"key":"782_CR5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"782_CR6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576 (2017).","journal-title":"Cell"},{"key":"782_CR7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","volume":"383","author":"JA Burger","year":"2020","unstructured":"Burger, J. A. Treatment of chronic lymphocytic leukemia. N. Engl. J. Med. 383, 460\u2013473 (2020).","journal-title":"N. Engl. J. Med."},{"key":"782_CR8","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1200\/JCO.2007.11.3886","volume":"25","author":"VC Jordan","year":"2007","unstructured":"Jordan, V. C. & O\u2019Malley, B. W. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 25, 5815\u20135824 (2007).","journal-title":"J. Clin. Oncol."},{"key":"782_CR9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701\u2013711 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"782_CR10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu, A. L. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324\u20131334 (2010).","journal-title":"N. Engl. J. Med."},{"key":"782_CR11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger, J. A. et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34, 787\u2013798 (2020).","journal-title":"Leukemia"},{"key":"782_CR12","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","volume":"2","author":"SZ Millis","year":"2016","unstructured":"Millis, S. Z., Ikeda, S., Reddy, S., Gatalica, Z. & Kurzrock, R. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors. JAMA Oncol. 2, 1565\u20131573 (2016).","journal-title":"JAMA Oncol."},{"key":"782_CR13","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","volume":"9","author":"H Hirai","year":"2010","unstructured":"Hirai, H. et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 9, 1956\u20131967 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"782_CR14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","volume":"11","author":"SM Maira","year":"2012","unstructured":"Maira, S. M. et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 11, 317\u2013328 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"782_CR15","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","volume":"7","author":"SM Maira","year":"2008","unstructured":"Maira, S. M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851\u20131863 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"782_CR16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","volume":"19","author":"A Di Leo","year":"2018","unstructured":"Di Leo, A. et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 87\u2013100 (2018).","journal-title":"Lancet Oncol."},{"key":"782_CR17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","volume":"560","author":"BD Hopkins","year":"2018","unstructured":"Hopkins, B. D. et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560, 499\u2013503 (2018).","journal-title":"Nature"},{"key":"782_CR18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(16)00106-6","volume":"17","author":"IE Krop","year":"2016","unstructured":"Krop, I. E. et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 17, 811\u2013821 (2016).","journal-title":"Lancet Oncol."},{"key":"782_CR19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997\u20131007 (2014).","journal-title":"N. Engl. J. Med."},{"key":"782_CR20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature 539, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"782_CR21","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/2326-6066.CIR-17-0143","volume":"5","author":"P Foubert","year":"2017","unstructured":"Foubert, P., Kaneda, M. M. & Varner, J. A. PI3K\u03b3 activates integrin \u03b14 and promotes immune suppressive myeloid cell polarization during tumor progression. Cancer Immunol. Res. 5, 957\u2013968 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"782_CR22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","volume":"19","author":"MC Schmid","year":"2011","unstructured":"Schmid, M. C. et al. Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3k\u03b3, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19, 715\u2013727 (2011).","journal-title":"Cancer Cell"},{"key":"782_CR23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda, M. M. et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature 539, 437\u2013442 (2016).","journal-title":"Nature"},{"key":"782_CR24","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong, D. S. et al. Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial. Clin. Cancer Res. 29, 2210\u20132219 (2023).","journal-title":"Clin. Cancer Res."},{"key":"782_CR25","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.2023022202","volume":"143","author":"H Gu","year":"2024","unstructured":"Gu, H. et al. PI3K\u03b3 maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood 143, 1965\u20131979 (2024).","journal-title":"Blood"},{"key":"782_CR26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526\u2013531 (2018).","journal-title":"Nature"},{"key":"782_CR27","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281 (2019).","journal-title":"Cell"},{"key":"782_CR28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng, S. W. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433\u2013437 (2016).","journal-title":"Nature"},{"key":"782_CR29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"N Cancer Genome Atlas Research","year":"2013","unstructured":"Cancer Genome Atlas Research, N. et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059\u20132074, (2013).","journal-title":"N. Engl. J. Med."},{"key":"782_CR30","doi-asserted-by":"crossref","first-page":"31059","DOI":"10.1074\/jbc.M113.508234","volume":"288","author":"A Shymanets","year":"2013","unstructured":"Shymanets, A. et al. p87 and p101 subunits are distinct regulators determining class IB phosphoinositide 3-kinase (PI3K) specificity. J. Biol. Chem. 288, 31059\u201331068 (2013).","journal-title":"J. Biol. Chem."},{"key":"782_CR31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0092-8674(00)80187-7","volume":"89","author":"LR Stephens","year":"1997","unstructured":"Stephens, L. R. et al. The G\u03b2\u03b3 sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89, 105\u2013114 (1997).","journal-title":"Cell"},{"key":"782_CR32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.molcel.2010.08.037","volume":"39","author":"Z Horejsi","year":"2010","unstructured":"Horejsi, Z. et al. CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability. Mol. Cell 39, 839\u2013850 (2010).","journal-title":"Mol. Cell"},{"key":"782_CR33","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt\/PKB by the rictor\u2013mTOR complex. Science 307, 1098\u20131101 (2005).","journal-title":"Science"},{"key":"782_CR34","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655\u20131657 (2002).","journal-title":"Science"},{"key":"782_CR35","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","volume":"24","author":"LV Pham","year":"2018","unstructured":"Pham, L. V. et al. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin. Cancer Res. 24, 3967\u20133980 (2018).","journal-title":"Clin. Cancer Res."},{"key":"782_CR36","doi-asserted-by":"crossref","first-page":"e0190854","DOI":"10.1371\/journal.pone.0190854","volume":"13","author":"A Sathe","year":"2018","unstructured":"Sathe, A. et al. Parallel PI3K, Akt and mTOR inhibition is required to control feedback loops that limit tumor therapy. PLoS ONE 13, e0190854 (2018).","journal-title":"PLoS ONE"},{"key":"782_CR37","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/0008-5472.CAN-03-3693","volume":"64","author":"S Tavor","year":"2004","unstructured":"Tavor, S. et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD\/SCID mice. Cancer Res. 64, 2817\u20132824 (2004).","journal-title":"Cancer Res."},{"key":"782_CR38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1042\/bj3210561","volume":"321","author":"TA Fields","year":"1997","unstructured":"Fields, T. A. & Casey, P. J. Signalling functions and biochemical properties of pertussis toxin-resistant G-proteins. Biochem. J. 321, 561\u2013571 (1997).","journal-title":"Biochem. J."},{"key":"782_CR39","doi-asserted-by":"crossref","first-page":"ra82","DOI":"10.1126\/scisignal.aae0453","volume":"9","author":"DM Houslay","year":"2016","unstructured":"Houslay, D. M. et al. Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3K\u03b2 in myeloid cells. Sci. Signal. 9, ra82 (2016).","journal-title":"Sci. Signal."},{"key":"782_CR40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","volume":"25","author":"DP Bondeson","year":"2018","unstructured":"Bondeson, D. P. et al. Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell Chem. Biol. 25, 78\u201387 (2018).","journal-title":"Cell Chem. Biol."},{"key":"782_CR41","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","volume":"57","author":"AD Buhimschi","year":"2018","unstructured":"Buhimschi, A. D. et al. Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation. Biochemistry 57, 3564\u20133575 (2018).","journal-title":"Biochemistry"},{"key":"782_CR42","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1021\/ja311795d","volume":"135","author":"EF Douglass Jr.","year":"2013","unstructured":"Douglass, E. F. Jr., Miller, C. J., Sparer, G., Shapiro, H. & Spiegel, D. A. A comprehensive mathematical model for three-body binding equilibria. J. Am. Chem. Soc. 135, 6092\u20136099 (2013).","journal-title":"J. Am. Chem. Soc."},{"key":"782_CR43","volume":"14","author":"RP Wurz","year":"2023","unstructured":"Wurz, R. P. et al. Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. Nat. Commun. 14, 4177 (2023).","journal-title":"Nat. Commun."},{"key":"782_CR44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","volume":"22","author":"J Lu","year":"2015","unstructured":"Lu, J. et al. Hijacking the E3 ubiquitin ligase Cereblon to efficiently target BRD4. Chem. Biol. 22, 755\u2013763 (2015).","journal-title":"Chem. Biol."},{"key":"782_CR45","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","volume":"38","author":"CC Chua","year":"2020","unstructured":"Chua, C. C. et al. Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J. Clin. Oncol. 38, 3506\u20133517 (2020).","journal-title":"J. Clin. Oncol."},{"key":"782_CR46","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","volume":"78","author":"M Rahmani","year":"2018","unstructured":"Rahmani, M. et al. Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer Res. 78, 3075\u20133086 (2018).","journal-title":"Cancer Res."},{"key":"782_CR47","volume":"6","author":"KH Lin","year":"2016","unstructured":"Lin, K. H. et al. Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia. Sci. Rep. 6, 27696 (2016).","journal-title":"Sci. Rep."},{"key":"782_CR48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1021\/acsmedchemlett.6b00238","volume":"7","author":"CA Evans","year":"2016","unstructured":"Evans, C. A. et al. Discovery of a selective phosphoinositide-3-kinase (PI3K)-\u03b3 inhibitor (IPI-549) as an immuno-oncology clinical candidate. ACS Med. Chem. Lett. 7, 862\u2013867 (2016).","journal-title":"ACS Med. Chem. Lett."},{"key":"782_CR49","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41589-018-0215-0","volume":"15","author":"G Gangadhara","year":"2019","unstructured":"Gangadhara, G. et al. A class of highly selective inhibitors bind to an active state of PI3K\u03b3. Nat. Chem. Biol. 15, 348\u2013357 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"782_CR50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tibs.2005.02.008","volume":"30","author":"B Vanhaesebroeck","year":"2005","unstructured":"Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B. & Foukas, L. C. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30, 194\u2013204 (2005).","journal-title":"Trends Biochem. Sci."},{"key":"782_CR51","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/biom9090427","volume":"9","author":"B N\u00fcrnberg","year":"2019","unstructured":"N\u00fcrnberg, B. & Beer-Hammer, S.Function, regulation and biological roles of PI3K\u03b3 variants. Biomolecules 9, 427 (2019).","journal-title":"Biomolecules"},{"key":"782_CR52","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1161\/CIRCRESAHA.111.262899","volume":"111","author":"A Perino","year":"2012","unstructured":"Perino, A., Ghigo, A., Scott, J. D. & Hirsch, E. Anchoring proteins as regulators of signaling pathways. Circ. Res. 111, 482\u2013492 (2012).","journal-title":"Circ. Res."},{"key":"782_CR53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2004.07.017","volume":"118","author":"E Patrucco","year":"2004","unstructured":"Patrucco, E. et al. PI3K\u03b3 modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375\u2013387 (2004).","journal-title":"Cell"},{"key":"782_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbior.2014.11.004","volume":"58","author":"M Beretta","year":"2015","unstructured":"Beretta, M., Bauer, M. & Hirsch, E. PI3K signaling in the pathogenesis of obesity: the cause and the cure. Adv. Biol. Regul. 58, 1\u201315 (2015).","journal-title":"Adv. Biol. Regul."},{"key":"782_CR55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1749-6632.2009.05081.x","volume":"1188","author":"F Damilano","year":"2010","unstructured":"Damilano, F., Perino, A. & Hirsch, E. PI3K kinase and scaffold functions in heart. Ann. N. Y. Acad. Sci. 1188, 39\u201345 (2010).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"782_CR56","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jmb.2017.01.023","volume":"429","author":"ML Mohan","year":"2017","unstructured":"Mohan, M. L. & Naga Prasad, S. V. Scaffolding function of PI3K\u03b3 emerges from enzyme\u2019s shadow. J. Mol. Biol. 429, 763\u2013772 (2017).","journal-title":"J. Mol. Biol."},{"key":"782_CR57","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376\u20131381 (2015).","journal-title":"Science"},{"key":"782_CR58","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","volume":"36","author":"L Bai","year":"2019","unstructured":"Bai, L. et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell 36, 498\u2013511 (2019).","journal-title":"Cancer Cell"},{"key":"782_CR59","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41589-022-01248-4","volume":"19","author":"A Kaneshige","year":"2023","unstructured":"Kaneshige, A. et al. A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo. Nat. Chem. Biol. 19, 703\u2013711 (2023).","journal-title":"Nat. Chem. Biol."},{"key":"782_CR60","doi-asserted-by":"crossref","first-page":"e202300141","DOI":"10.1002\/cbic.202300141","volume":"24","author":"E Koide","year":"2023","unstructured":"Koide, E. et al. Development and characterization of selective FAK inhibitors and PROTACs with in vivo activity. Chembiochem 24, e202300141 (2023).","journal-title":"Chembiochem"},{"key":"782_CR61","volume":"10","author":"B Langmead","year":"2009","unstructured":"Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).","journal-title":"Genome Biol."},{"key":"782_CR62","doi-asserted-by":"crossref","first-page":"W160","DOI":"10.1093\/nar\/gkw257","volume":"44","author":"F Ramirez","year":"2016","unstructured":"Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160\u2013W165 (2016).","journal-title":"Nucleic Acids Res."},{"key":"782_CR63","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/bioinformatics\/btu056","volume":"30","author":"A Pohl","year":"2014","unstructured":"Pohl, A. & Beato, M. bwtool: a tool for bigWig files. Bioinformatics 30, 1618\u20131619 (2014).","journal-title":"Bioinformatics"},{"key":"782_CR64","doi-asserted-by":"crossref","first-page":"ra121","DOI":"10.1126\/scisignal.aaa1877","volume":"7","author":"CA Martz","year":"2014","unstructured":"Martz, C. A. et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci. Signal. 7, ra121 (2014).","journal-title":"Sci. Signal."},{"key":"782_CR65","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/2159-8290.CD-19-0970","volume":"10","author":"A Su","year":"2020","unstructured":"Su, A. et al. The folate cycle enzyme MTHFR is a critical regulator of cell response to MYC-targeting therapies. Cancer Discov. 10, 1894\u20131911 (2020).","journal-title":"Cancer Discov."},{"key":"782_CR66","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s43018-022-00394-x","volume":"3","author":"KH Lin","year":"2022","unstructured":"Lin, K. H. et al. P2RY2\u2013Akt activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. Nat. Cancer 3, 837\u2013851 (2022).","journal-title":"Nat. Cancer"},{"key":"782_CR67","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).","journal-title":"Nucleic Acids Res."},{"key":"782_CR68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccr.2005.12.014","volume":"9","author":"YH Kuo","year":"2006","unstructured":"Kuo, Y. H. et al. Cbf\u03b2-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell 9, 57\u201368 (2006).","journal-title":"Cancer Cell"},{"key":"782_CR69","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nmeth.4324","volume":"14","author":"H Pimentel","year":"2017","unstructured":"Pimentel, H., Bray, N. L., Puente, S., Melsted, P. & Pachter, L. Differential analysis of RNA-seq incorporating quantification uncertainty. Nat. Methods 14, 687\u2013690 (2017).","journal-title":"Nat. Methods"},{"key":"782_CR70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 14, 7 (2013).","journal-title":"BMC Bioinf."},{"key":"782_CR71","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461 (2010).","journal-title":"J. Comput. Chem."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00782-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00782-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00782-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T13:14:43Z","timestamp":1722258883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00782-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":71,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1038\/s43018-024-00782-5","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Krogan Laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche and Rezo Therapeutics. N.J.K. has financially compensated consulting agreements with Maze Therapeutics. N.J.K. is the president and on the board of directors of Rezo Therapeutics and a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics and Interline Therapeutics. K.C.W. is a cofounder, consultant and equity holder at Tavros Therapeutics and Celldom, is a consultant and equity holder at Simple Therapeutics and Decrypt Biomedicine and has performed consulting work for Guidepoint Global, Bantam Pharmaceuticals and Apple Tree Partners. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}